Effectiveness of ORAl hydroxocobalamin in treatment of vitamin B12 deficiency with neurological manifestations

Effectiveness of ORAl hydroxocobalamin in treatment of vitamin B12 deficiency with neurological manifestations: a single-centre, prospective, open-label study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN92106665

Enrollment

Registered

2011-09-02

Start date

2011-01-03

Completion date

Unknown

Last updated

2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin B12 deficiency Nutritional, Metabolic, Endocrine Vitamin B12 deficiency

Interventions

1. Oral hydroxocobalamin dose: 15000 ug/day (5000 X 3/day) is administered at days 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 2. After that 15000 ug/month (administered once every month)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Presence of neurological signs due to vitamin B12 deficiency, unexplained by other causes, with a rate of serum vitamin B12 <200 pg / ml

Exclusion criteria

Exclusion criteria: 1. Patients previously treated for vitamin B12 deficiency 2. Patients aged under 18 or over 80 years 3. Patients with vitamin B12 deficiency corrected without resorting to the long-term supplementation

Design outcomes

Primary

Measure	Time frame
Serum vitamin B12 level on days 10 and 90	—

Secondary

Measure	Time frame
1. Haematological parameters : Hemoglobin level, mean corpuscular volume (MCV), reticulocytE number, white cells and platelets 2. Neurological improvement : questionnaires e.g. mini?mental state examination (MMSE), neurological exam with sense vibration tested by diapazon 128 Hz. Measured at days 10 and 90	—

Countries

Morocco

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026